Acadian Asset Management
KRSA

Acadian Asset Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Acadian Asset Management’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-319
Closed -$7K – 1697
2023
Q3 		$7K Sell
319
-458
-59% -$1.65K ﹤0.01% 1605
2023
Q2 		$22K Sell
777
-880
-53% -$4.56K ﹤0.01% 1639
2023
Q1 		$99K Hold
1,657
– – ﹤0.01% 1397
2022
Q4 		$151K Hold
1,657
– – ﹤0.01% 1350
2022
Q3 		$198K Hold
1,657
– – ﹤0.01% 1215
2022
Q2 		$127K Hold
1,657
– – ﹤0.01% 1304
2022
Q1 		$256K Sell
1,657
-127
-7% -$3.06K ﹤0.01% 1154
2021
Q4 		$428K Buy
+1,784
New +$84.3K ﹤0.01% 1050
2021
Q1 		– Sell
-368
Closed -$157K – 2108
2020
Q4 		$157K Buy
368
+87
+31% +$5.93K ﹤0.01% 1630
2020
Q3 		$239K Sell
281
-813
-74% -$93K ﹤0.01% 1385
2020
Q2 		$905K Buy
1,094
+324
+42% +$27.1K ﹤0.01% 995
2020
Q1 		$285K Buy
770
+50
+7% +$3.57K ﹤0.01% 1110
2019
Q4 		$274K Buy
+720
New +$67.2K ﹤0.01% 1217

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management's KRSA Position: Q4 2023 in Review

Acadian Asset Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2023, closing a stake of 319 shares — an estimated $7K sold.

Acadian Asset Management first reported a position in KRSA in Q4 2019 and held it in 13 quarters. The position peaked at $905K in Q2 2020. 14 funds tracked by Wall St. Rank hold KRSA as of Q4 2023.

  • Acadian Asset Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Acadian Asset Management sold 319 Korsana Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $7K.
  • Acadian Asset Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q4 2019 and held it in 13 quarters.
  • Acadian Asset Management's Korsana Biosciences, Inc. Common Stock position peaked at $905K in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2023.

Based on Acadian Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.